Recognising and managing HLH: what’s changed in the updated GIRFT pathway?

Recognising and managing HLH: what’s changed in the updated GIRFT pathway?

GIRFT has updated the consensus pathway and supporting guidance for the diagnosis, treatment, management and governance of the rare condition, haemophagocytic lymphohistiocytosis (HLH). 

Dr Peter Lanyon, GIRFT joint clinical lead for rheumatology, is hosting this webinar to discuss why the pathway matters and what has changed in the updated version. 

HLH is a rare and devastating syndrome with uncontrolled activation of the immune system leading to hyperinflammation, tissue damage and multi-organ failure. GIRFT’s ambition is to increase awareness of HLH and emphasise the importance of working across specialties to diagnose the condition, to improve the care and outcomes for people with HLH.

The pathway has been updated by rheumatologists Dr Rachel Tattersall (Sheffield Teaching Hospitals and Sheffield Children’s Hospital) and Dr Jessica Manson (University College London Hospitals). In this webinar, Dr Manson will outline the changes and how adopting the pathway can make a difference to patients. Dr Tattersall will discuss how to recognise HLH, the diagnostic approach, common pitfalls and the need for early action.

The webinar will also include case studies from colleagues on putting the pathway into practice, multidisciplinary working, and learning from national networks.

The joining link will be sent by separate email nearer the event date. 

Questions about this event?

Questions about this event?

Name: sophie sheard

Email: sophie.sheard1@nhs.net

Telephone: 07876 478799